we develop immunologic therapeutics and diagnostics designed to make the world a healthier place
Company profile
Ticker
REVB
Exchange
Website
CEO
Andreas Typaldos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Petra Acquisition Inc.
SEC CIK
Corporate docs
IRS number
843898466
REVB stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
8 Feb 24
424B3
Prospectus supplement
2 Feb 24
EFFECT
Notice of effectiveness
1 Feb 24
8-K
Developing innovative therapeutics to address unmet needs Corporate Presentation / January 2024 www.revbiosciences.com
30 Jan 24
S-1/A
IPO registration (amended)
30 Jan 24
CORRESP
Correspondence with SEC
30 Jan 24
S-1/A
IPO registration (amended)
29 Jan 24
Latest ownership filings
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
SABBY MANAGEMENT, LLC
3 Jan 24
4
GEORGE F TIDMARSH
12 Dec 23
4
GEORGE F TIDMARSH
18 Oct 23
4
GEORGE F TIDMARSH
17 Oct 23
3
Lakhmir S Chawla
2 Oct 23
4
GEORGE F TIDMARSH
2 Oct 23
144
Notice of proposed sale of securities
28 Sep 23
4
GEORGE F TIDMARSH
18 Sep 23
4
GEORGE F TIDMARSH
19 Apr 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.99 mm | 13.99 mm | 13.99 mm | 13.99 mm | 13.99 mm | 13.99 mm |
Cash burn (monthly) | 572.23 k | (no burn) | 925.97 k | 629.09 k | 572.23 k | 519.24 k |
Cash used (since last report) | 3.42 mm | n/a | 5.53 mm | 3.76 mm | 3.42 mm | 3.10 mm |
Cash remaining | 10.58 mm | n/a | 8.46 mm | 10.24 mm | 10.58 mm | 10.89 mm |
Runway (months of cash) | 18.5 | n/a | 9.1 | 16.3 | 18.5 | 21.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 15 |
Closed positions | 6 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 709.78 mm |
Total shares | 5.53 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AXA IM Prime Impact Master Fund I SCA SICAV-RAIF | 1.96 mm | $0.00 |
Linden Advisors | 715.75 k | $12.81 mm |
Linden Capital | 715.75 k | $0.00 |
Walleye Capital | 496.14 k | $296.17 mm |
Sabby Management | 353.23 k | $332.04 mm |
Yakira Capital Management | 246.88 k | $4.40 mm |
Lind Global Fund II | 186.50 k | $533.00 k |
Intracoastal Capital | 184.98 k | $511.00 k |
Walleye Trading | 104.99 k | $1.87 mm |
Cowen And | 98.30 k | $1.75 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Dec 23 | George F Tidmarsh | Common Stock | Sell | Dispose S | No | No | 0.5199 | 27,771 | 14.44 k | 0 |
16 Oct 23 | George F Tidmarsh | Common Stock | Sell | Dispose S | Yes | No | 0.661 | 10,957 | 7.24 k | 42,096 |
16 Oct 23 | George F Tidmarsh | Common Stock | Sell | Dispose S | No | No | 0.6501 | 1,845 | 1.20 k | 27,771 |
28 Sep 23 | George F Tidmarsh | Common Stock | Sell | Dispose S | Yes | No | 0.69 | 1,429 | 986.01 | 42,096 |
News
Revelation Biosciences Q4 EPS $(8.33) Beats $(13.77) Estimate
22 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
14 Mar 24
Revelation Biosciences Presented Data Showing Pretreatment With Gemini, Improved Kidney Function With Reduced Serum Blood Urea Nitrogen And Creatinine, Urine C-reactive Protein, And Acute Kidney Injury-Related Inflammation
12 Mar 24
Revelation Biosciences Commences First In Human Phase 1 Clinical Study Of Gemini
4 Mar 24
Top 5 Health Care Stocks That Are Preparing To Pump In February
9 Feb 24
Press releases
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
22 Mar 24
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
13 Mar 24
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
4 Mar 24
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
12 Feb 24
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
5 Feb 24